Syngene Intl.

Who are the top shareholders of the Syngene Intl.?

The top shareholders of Syngene International are Biocon Limited with 52.46%, mutual funds at 17.86%, and foreign institutional investors holding 19.47%. The highest public shareholder is ICICI Prudential Innovation Fund with a 5.13% stake, while individual investors own about 5.08%.

The top shareholders of Syngene International include Biocon Limited, which holds the largest stake at 52.46%. Other significant shareholders are mutual funds, which collectively own 17.86% of the company, and foreign institutional investors (FIIs) who hold 19.47%. The highest public shareholder is ICICI Prudential Innovation Fund, with a 5.13% stake. Additionally, individual investors own about 5.08% of the shares.

When is the next results date for Syngene Intl.?

No Upcoming Board Meetings

Who are in the management team of Syngene Intl.?

As of March 2022, the management team of Syngene International includes Kiran Mazumdar Shaw (Chairperson), Jonathan Hunt (Managing Director & CEO), and several independent directors, bringing diverse expertise to the company.

As of March 2022, the management team of Syngene International includes:<BR><BR>1. Kiran Mazumdar Shaw - Chairperson<BR>2. Catherine Patricia Rosenberg - Director<BR>3. Paul Frederick Blackburn - Independent Director<BR>4. Vijay Kuchroo - Independent Director<BR>5. Jonathan Hunt - Managing Director & CEO<BR>6. Vinita Bali - Lead Independent Director<BR>7. Priyadarshnini Mahapatra - Company Secretary & Compliance Officer<BR>8. Sharmila Karve - Independent Director<BR>9. Carl Decicco - Director<BR>10. Kush Parmar - Independent Director<BR><BR>This team brings a diverse range of expertise and leadership to the company.

What does Syngene Intl. do?

Syngene International Limited is a large-cap integrated research, development, and manufacturing services organization in the healthcare sector, with recent net sales of ₹1,018 Cr and a net profit of ₹183 Cr for the quarter ending March 2025. The company has a market cap of ₹26,022 Cr and key metrics include a P/E ratio of 55.00 and a dividend yield of 0.19%.

Overview:<BR>Syngene International Limited is an integrated research, development, and manufacturing services organization operating in the healthcare services industry and classified as a large-cap company.<BR><BR>History:<BR>Syngene International was incorporated in an unspecified year and has maintained its status as a leading service provider in the healthcare sector. The latest quarterly results reported net sales and net profit for the period ending March 2025.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 1,018 Cr (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: 183 Cr (Quarterly Results - Mar 2025) <BR>Market-cap value: Rs 26,022 Cr (Large Cap)<BR><BR>Key Metrics:<BR>P/E: 55.00 <BR>Industry P/E: 35 <BR>Dividend Yield: 0.19% <BR>Debt-Equity: -0.17 <BR>Return on Equity: 9.99% <BR>Price-to-Book: 5.52 <BR><BR>Contact Details:<BR>Address: Biocon SEZ Biocon Park, Plot No 2 & 3 Bommasandra Inds Bengaluru Karnataka : 560099 <BR>Phone: 91-80-68915000/67758781 <BR>Email: investor@syngeneintl.com <BR>Website: http://www.syngeneintl.com

What is the bonus history of the Syngene Intl.?

Syngene International Ltd announced a 1:1 bonus issue on June 11, 2019, with a record date of June 12, 2019, allowing shareholders to receive one additional share for each share held.

Syngene International Ltd has a bonus history that includes a 1:1 bonus issue announced on June 11, 2019. The record date for this bonus was June 12, 2019. This means that shareholders received one additional share for every share they held as of the record date.

Has Syngene Intl. declared dividend?

Syngene International Ltd has declared a dividend of 12% (₹1.2 per share) with an ex-date of June 28, 2024. While recent total returns have been negative, longer-term performance shows positive growth.

Syngene International Ltd has declared a dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 12%<BR>- Amount per share: 1.2<BR>- Ex-date: Jun-28-2024<BR><BR>Dividend Yield: 0.19%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -30.02%, the dividend return was 0.14%, resulting in a total return of -29.88%.<BR><BR>Over the past year, the price return was -5.96%, the dividend return was 0.34%, leading to a total return of -5.62%.<BR><BR>For the 2-year period, the price return was -12.31%, the dividend return was 0.42%, culminating in a total return of -11.89%.<BR><BR>In the last 3 years, the price return was 20.73%, the dividend return was 0.65%, resulting in a total return of 21.38%.<BR><BR>Over the past 4 years, the price return was 9.33%, the dividend return was 0.62%, leading to a total return of 9.95%.<BR><BR>In the 5-year period, the price return was 74.97%, the dividend return was 0.89%, culminating in a total return of 75.86%.<BR><BR>Overall, while Syngene International Ltd has declared a dividend, the total returns over various periods show a mixed performance, with significant declines in the short term but positive returns over the longer term.

Who are the peers of the Syngene Intl.?

Syngene Intl.'s peers include Dr Lal Pathlabs, Poly Medicure, Indegene, Vijaya Diagnost., Metropolis Health, Thyrocare Tech., Suven Life Sciences, Laxmi Dental, and Vimta Labs. Syngene has good management risk but below-average growth and the lowest 1-year return among its peers at -3.62%.

Peers: The peers of Syngene Intl. are Dr Lal Pathlabs, Poly Medicure, Indegene, Vijaya Diagnost., Metropolis Healt, Thyrocare Tech., Suven Life Scie., Laxmi Dental, and Vimta Labs.<BR><BR>Quality Snapshot: Excellent management risk is observed at Dr Lal Pathlabs and Laxmi Dental, while Good management risk is found at Syngene Intl., Poly Medicure, Indegene, Vijaya Diagnost., Metropolis Healt, Thyrocare Tech., and Vimta Labs, and the rest. Below Average management risk is noted at Suven Life Scie. and Average management risk is found at Krsnaa Diagnost. Growth is Good at Laxmi Dental, Average at Poly Medicure, Indegene, and Vimta Labs, while Below Average growth is observed at Syngene Intl., Dr Lal Pathlabs, Vijaya Diagnost., Metropolis Healt, Thyrocare Tech., and the rest, with Suven Life Scie. showing Below Average growth. Excellent capital structure is seen at Dr Lal Pathlabs, Poly Medicure, Indegene, Vijaya Diagnost., Metropolis Healt, Thyrocare Tech., and Krsnaa Diagnost., while Good capital structure is noted at Laxmi Dental, and Below Average at Suven Life Scie.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Suven Life Scie. at 160.99%, while the lowest is Syngene Intl. at -3.62%. Syngene Intl.'s 1-year return is lower than that of all its peers. Additionally, the six-month return is negative for Syngene Intl., Poly Medicure, Vijaya Diagnost., Metropolis Healt, and Krsnaa Diagnost.

How big is Syngene Intl.?

As of 24th July, Syngene International Ltd has a market capitalization of 26,910.00 Cr, with recent net sales of 3,727.20 Cr and a net profit of 507.20 Cr.

As of 24th July, Syngene International Ltd has a market capitalization of 26,910.00 Cr, categorizing it as a Large Cap company.<BR><BR>In the latest four quarters, Syngene reported Net Sales of 3,727.20 Cr and a Net Profit of 507.20 Cr.<BR><BR>The latest annual period for the balance sheet is March 2025, with Shareholder's Funds amounting to 4,726.80 Cr and Total Assets of 6,766.50 Cr.

How has been the historical performance of Syngene Intl.?

Syngene Intl. has shown consistent growth in net sales and operating profit from INR 1,825.60 crore in March 2019 to INR 3,642.40 crore in March 2025, although profit after tax slightly declined in 2025. Total assets and cash flow from operations have also improved significantly during this period.

Answer:<BR>The historical performance of Syngene Intl. shows a consistent growth trajectory in net sales and profits over the years.<BR><BR>Breakdown:<BR>Syngene Intl. has demonstrated a strong upward trend in net sales, increasing from INR 1,825.60 crore in March 2019 to INR 3,642.40 crore in March 2025. This growth is reflected in the total operating income, which also rose from INR 1,825.60 crore to INR 3,642.40 crore during the same period. The company's operating profit (PBDIT) has similarly improved, reaching INR 1,113.60 crore in March 2025, up from INR 611.90 crore in March 2019. However, profit after tax showed a slight decline from INR 510.00 crore in March 2024 to INR 496.20 crore in March 2025. The total assets of Syngene increased significantly from INR 4,040.20 crore in March 2020 to INR 6,766.50 crore in March 2025, while total liabilities also rose from INR 4,040.20 crore to INR 6,766.50 crore in the same timeframe. Cash flow from operating activities has improved, reaching INR 1,167.00 crore in March 2025, compared to INR 677.00 crore in March 2020, indicating a positive cash generation trend. Overall, Syngene Intl. has shown robust growth in revenue and operational efficiency, despite some fluctuations in net profit.

Is Syngene Intl. technically bullish or bearish?

As of December 4, 2025, Syngene Intl. shows a mildly bearish trend, with daily moving averages and Bollinger Bands indicating bearishness, despite some mildly bullish signals from the weekly MACD.

As of 4 December 2025, the technical trend for Syngene Intl. has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by the daily moving averages indicating a bearish outlook and the weekly OBV also showing mild bearishness. The MACD on the weekly chart is mildly bullish, but the monthly MACD remains bearish, suggesting mixed signals across time frames. The Bollinger Bands are bearish on both weekly and monthly charts, reinforcing the bearish sentiment. Overall, while there are some mildly bullish indicators, the prevailing trend remains bearish.

Are Syngene International Ltd latest results good or bad?

Syngene International Ltd's latest Q3 FY26 results are concerning, with net profit down 88.56% year-on-year to ₹15.00 crores and a PAT margin collapsing to 1.64%. Revenue growth was minimal, raising concerns about the company's sustainability and operational efficiency.

Syngene International Ltd's latest results for Q3 FY26 are concerning and can be classified as bad. The company experienced a significant decline in profitability, with net profit plummeting by 88.56% year-on-year to just ₹15.00 crores. This represents a catastrophic drop from the previous year and marks the lowest quarterly profit in recent history.<BR><BR>Additionally, the profit after tax (PAT) margin collapsed to a mere 1.64%, down from 13.89% in the same quarter last year. Revenue growth was also tepid, with only a 0.71% increase quarter-on-quarter, and a 2.82% decline year-on-year. The elevated tax rate of 47.18% further exacerbated the situation, consuming a significant portion of the already diminished profit before tax.<BR><BR>Overall, the results raise serious questions about the sustainability of Syngene's business model and operational efficiency, indicating a troubling trend that investors should be wary of.

Should I buy, sell or hold Syngene International Ltd?

Why is Syngene International Ltd falling/rising?

As of 23-Mar, Syngene International Ltd's stock price is at Rs 396.55, down 4.37%, reflecting significant underperformance with a year-to-date drop of 39.08% and a return of -44.57% over the past year. Factors contributing to this decline include poor financial results, declining liquidity, and negative sentiment in the pharmaceutical sector.

As of 23-Mar, Syngene International Ltd's stock price is falling, currently at Rs 396.55, reflecting a decrease of Rs 18.1 or 4.37%. This decline can be attributed to several factors. The stock has underperformed the broader market, with a year-to-date drop of 39.08% compared to a 14.70% decline in the benchmark index. Over the past year, the stock has generated a return of -44.57%, significantly underperforming the BSE500, which has seen a much smaller decrease of 5.47%.<BR><BR>Today's performance indicates that the stock is trading lower than its moving averages across various time frames, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages. Additionally, the stock is close to its 52-week low, just 3.91% above the low of Rs 381.05. The stock's liquidity appears to be declining, as evidenced by a 32.07% drop in delivery volume compared to the 5-day average.<BR><BR>Financially, the company has reported negative results, with a significant fall in profit before tax and profit after tax in the most recent quarter. The company's return on equity stands at 9.9, and it is trading at a premium valuation with a Price to Book Value of 3.4, which is considered expensive compared to its peers. Furthermore, the pharmaceutical sector, in which Syngene operates, has also seen a decline of 3.58%, contributing to the negative sentiment surrounding the stock.<BR><BR>Overall, the combination of poor financial performance, declining investor participation, and underwhelming sector performance has led to the stock's downward trajectory.

Why is Syngene International Ltd falling/rising?

As of 24-Mar, Syngene International Ltd's stock price is Rs 398.90, showing a slight increase today but a significant decline of 38.72% year-to-date and 44.44% over the past year. The stock is underperforming against its sector and key benchmarks, indicating a bearish trend and a general perception of it as a strong sell.

As of 24-Mar, Syngene International Ltd's stock price is currently at Rs 398.90, reflecting a slight increase of 0.85 (0.21%). However, the stock has shown a significant decline over various time periods, including a year-to-date drop of 38.72% and a one-year decline of 44.44%. This underperformance is starkly contrasted with the benchmark Sensex, which has only decreased by 13.09% over the same year.<BR><BR>The stock's performance today indicates it is 4.74% away from its 52-week low of Rs 381.05 and has underperformed its sector by 0.63%. Additionally, it is trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, which suggests a bearish trend. The delivery volume has also decreased significantly, falling by 19.83% compared to the 5-day average, indicating a decline in investor participation.<BR><BR>Financially, the company has reported poor long-term growth, with net sales growing at an annual rate of only 11.77% and operating profit at 5.36% over the last five years. Recent quarterly results have been disappointing, with profit before tax falling by 37.8% and profit after tax dropping by 55.3% compared to previous quarters. The stock's valuation appears expensive, trading at a price-to-book value of 3.4, which is higher than its peers, and it has consistently underperformed against the benchmark over the last three years.<BR><BR>In summary, despite a minor rise in the stock price today, the overall trend and financial performance indicate that Syngene International Ltd is facing significant challenges, leading to a general perception of the stock as a strong sell.

Why is Syngene International Ltd falling/rising?

As of 25-Mar, Syngene International Ltd's stock price is rising to Rs 421.00, up 5.54%, driven by short-term trading dynamics and increased investor participation, despite a significant year-to-date decline of 35.32% and negative financial results.

As of 25-Mar, Syngene International Ltd's stock price is rising, currently at Rs 421.00, reflecting an increase of Rs 22.1 or 5.54%. This upward movement can be attributed to several factors. Firstly, the stock has outperformed its sector by 3.65% today and has shown consecutive gains over the last two days, accumulating a total return of 5.77% during this period. Additionally, the stock reached an intraday high of Rs 423.05, indicating strong buying interest.<BR><BR>Investor participation has also increased, with a delivery volume of 4.87 lacs on March 24, which is a 5.4% rise compared to the 5-day average delivery volume. This suggests that more investors are willing to hold the stock, contributing to its price rise. Furthermore, the stock is currently trading above its 5-day and 20-day moving averages, which can be a positive technical indicator for traders.<BR><BR>Despite these positive short-term movements, it is important to note that Syngene International Ltd has experienced significant underperformance over the longer term, with a year-to-date decline of 35.32% and a one-year return of -40.94%. The company has also reported negative financial results recently, including a substantial drop in profit before tax and profit after tax compared to previous quarters. However, the current rise in stock price appears to be driven by short-term trading dynamics rather than a fundamental improvement in the company's financial health.

Which are the latest news on Syngene Intl.?